Caladrius SEC Filing | Lisata Therapeutics, Inc.

Filing date	Form	Description	View
May 9, 2017	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0000320017-17-000037.pdf 0000320017-17-000037.rtf
May 5, 2017	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0000320017-17-000035.pdf 0000320017-17-000035.rtf 0000320017-17-000035.xls
May 1, 2017	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0000320017-17-000033.pdf 0000320017-17-000033.rtf
Apr 27, 2017	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0000320017-17-000029.pdf 0000320017-17-000029.rtf
Apr 27, 2017	4	Statement of changes in beneficial ownership of securities	View HTML 0001144204-17-022653.pdf 0001144204-17-022653.rtf 0001144204-17-022653.xls
Apr 27, 2017	4	Statement of changes in beneficial ownership of securities	View HTML 0001144204-17-022654.pdf 0001144204-17-022654.rtf 0001144204-17-022654.xls
Apr 27, 2017	4	Statement of changes in beneficial ownership of securities	View HTML 0001144204-17-022656.pdf 0001144204-17-022656.rtf 0001144204-17-022656.xls
Apr 27, 2017	4	Statement of changes in beneficial ownership of securities	View HTML 0001144204-17-022666.pdf 0001144204-17-022666.rtf 0001144204-17-022666.xls
Apr 27, 2017	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0000320017-17-000031.pdf 0000320017-17-000031.rtf
Apr 11, 2017	DEFM14A	Definitive proxy statement relating to merger or acquisition	View HTML 0001571049-17-003364.pdf 0001571049-17-003364.rtf 0001571049-17-003364.xls